J. Fisher, G. Rodan, and A. Reszka, Effects of Bisphosphonates on the Osteoclast Mevalonate Pathway, Endocrinology, vol.141, issue.12, pp.4793-4796, 2000.
DOI : 10.1210/endo.141.12.7921

J. Fisher, M. Rogers, J. Halasy, S. Luckman, D. Hughes et al., Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro, Proceedings of the National Academy of Sciences, vol.96, issue.1, pp.133-138, 1999.
DOI : 10.1073/pnas.96.1.133

D. Hughes, K. Wright, H. Uy, A. Sasaki, T. Yoneda et al., Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo, Journal of Bone and Mineral Research, vol.11, issue.2, pp.1478-1487, 1995.
DOI : 10.1002/jbmr.5650101008

S. Luckman, D. Hughes, F. Coxon, R. Graham, G. Russell et al., Nitrogen-Containing Bisphosphonates Inhibit the Mevalonate Pathway and Prevent Post-Translational Prenylation of GTP-Binding Proteins, Including Ras, Journal of Bone and Mineral Research, vol.8, issue.Suppl 4, pp.581-589, 1998.
DOI : 10.1359/jbmr.1998.13.4.581

M. Rogers, J. Frith, S. Luckman, F. Coxon, H. Benford et al., Molecular mechanisms of action of bisphosphonates, Bone, vol.24, issue.5, pp.73-79, 1999.
DOI : 10.1016/S8756-3282(99)00070-8

P. Chavassieux, M. Arlot, C. Reda, L. Wei, A. Yates et al., Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis., Journal of Clinical Investigation, vol.100, issue.6, pp.1475-1480, 1997.
DOI : 10.1172/JCI119668

C. Rosen, M. Hochberg, S. Bonnick, M. Mcclung, P. Miller et al., Treatment With Once-Weekly Alendronate 70 mg Compared With Once-Weekly Risedronate 35 mg in Women With Postmenopausal Osteoporosis: A Randomized Double-Blind Study, Journal of Bone and Mineral Research, vol.13, issue.1, pp.141-151, 2005.
DOI : 10.1359/JBMR.040920

P. Delmas, How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?, Bone, vol.27, issue.1, pp.1-3, 2000.
DOI : 10.1016/S8756-3282(00)00301-X

N. Giuliani, M. Pedrazzoni, G. Negri, G. Passeri, M. Impicciatore et al., Bisphosphonates Stimulate Formation of Osteoblast Precursors and Mineralized Nodules in Murine and Human Bone Marrow Cultures In Vitro and Promote Early Osteoblastogenesis in Young and Aged Mice In Vivo, Bone, vol.22, issue.5, pp.455-461, 1998.
DOI : 10.1016/S8756-3282(98)00033-7

G. Im, S. Qureshi, J. Kenney, H. Rubash, and A. Shanbhag, Osteoblast proliferation and maturation by bisphosphonates, Biomaterials, vol.25, issue.18, pp.4105-4115, 2004.
DOI : 10.1016/j.biomaterials.2003.11.024

A. Schindeler and D. Little, Osteoclasts but not osteoblasts are affected by a calcified surface treated with zoledronic acid in vitro, Biochemical and Biophysical Research Communications, vol.338, issue.2, pp.710-716, 2005.
DOI : 10.1016/j.bbrc.2005.09.198

L. Plotkin, R. Weinstein, A. Parfitt, P. Roberson, S. Manolagas et al., Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin, Journal of Clinical Investigation, vol.104, issue.10, pp.1363-1374, 1999.
DOI : 10.1172/JCI6800

G. Rodan and H. Fleisch, Bisphosphonates: mechanisms of action., Journal of Clinical Investigation, vol.97, issue.12, pp.2692-2696, 1996.
DOI : 10.1172/JCI118722

D. Bikle, E. Morey-holton, S. Doty, P. Currier, S. Tanner et al., Alendronate increases skeletal mass of growing rats during unloading by inhibiting resorption of calcified cartilage, Journal of Bone and Mineral Research, vol.6, issue.11, pp.1777-1787, 1994.
DOI : 10.1002/jbmr.5650091115

T. Mashiba, T. Hirano, C. Turner, M. Forwood, C. Johnston et al., Suppressed Bone Turnover by Bisphosphonates Increases Microdamage Accumulation and Reduces Some Biomechanical Properties in Dog Rib, Journal of Bone and Mineral Research, vol.23, issue.Suppl, pp.613-620, 2000.
DOI : 10.1359/jbmr.2000.15.4.613

T. Mashiba, C. Turner, T. Hirano, M. Forwood, C. Johnston et al., Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles, Bone, vol.28, issue.5, pp.524-531, 2001.
DOI : 10.1016/S8756-3282(01)00414-8

S. Olivier, M. Fillet, M. Malaise, J. Piette, V. Bours et al., Sodium nitroprusside-induced osteoblast apoptosis is mediated by long chain ceramide and is decreased by raloxifene, Biochemical Pharmacology, vol.69, issue.6, pp.891-901, 2005.
DOI : 10.1016/j.bcp.2004.11.030
URL : http://orbi.ulg.ac.be/jspui/handle/2268/21167

V. Viereck, C. Grundker, S. Blaschke, B. Niederkleine, H. Siggelkow et al., Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts The selective estrogen receptor modulator raloxifene regulates osteoclast and osteoblast activity in vitro, J Clin Endocrinol Metab Bone, vol.88, issue.30, pp.368-376, 2002.

C. Lees, T. Register, C. Turner, T. Wang, M. Stancill et al., Effects of raloxifene on bone density, biomarkers, and histomorphometric and biomechanical measures in ovariectomized cynomolgus monkeys, Menopause, vol.9, issue.5, pp.320-328, 2002.
DOI : 10.1097/00042192-200209000-00004

J. Iwamoto, J. Yeh, A. Schmidt, E. Rowley, L. Stanfield et al., Raloxifene and Vitamin K2 Combine to Improve the Femoral Neck Strength of Ovariectomized Rats, Calcified Tissue International, vol.39, issue.2, pp.119-126, 2005.
DOI : 10.1007/s00223-004-0277-8

S. Ott, A. Oleksik, Y. Lu, K. Harper, and P. Lips, Bone Histomorphometric and Biochemical Marker Results of a 2-Year Placebo-Controlled Trial of Raloxifene in Postmenopausal Women, Journal of Bone and Mineral Research, vol.6, issue.2, pp.341-348, 2002.
DOI : 10.1359/jbmr.2002.17.2.341

H. Frost, The Utah Paradigm of Skeletal Physiology, Chapters 3 and 4. International Society of Musculoskeletal and Neuronal Interactions, 2004.

R. Erben, Trabecular and endocortical bone surfaces in the rat: Modeling or remodeling?, The Anatomical Record, vol.64, issue.1, pp.39-46, 1996.
DOI : 10.1002/(SICI)1097-0185(199609)246:1<39::AID-AR5>3.0.CO;2-A

E. Eriksen, F. Melsen, E. Sod, I. Barton, and A. Chines, Effects of long-term risedronate on bone quality and bone turnover in women with postmenopausal osteoporosis, Bone, vol.31, issue.5, pp.620-625, 2002.
DOI : 10.1016/S8756-3282(02)00869-4

A. Parfitt, M. Drezner, F. Glorieux, J. Kanis, H. Malluche et al., Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committee, Journal of Bone and Mineral Research, vol.10, issue.6, pp.595-610, 1987.
DOI : 10.1002/jbmr.5650020617

S. Bord, A. Horner, S. Beavan, and J. Compston, Estrogen receptors alpha and beta are differentially expressed in developing human bone, J Clin Endocrinol Metab, vol.86, pp.2309-2314, 2001.

O. Vidal, M. Lindberg, K. Hollberg, D. Baylink, G. Andersson et al., Estrogen receptor specificity in the regulation of skeletal growth and maturation in male mice, Proceedings of the National Academy of Sciences, vol.97, issue.10, pp.5474-5479, 2000.
DOI : 10.1073/pnas.97.10.5474

N. Sims, S. Dupont, A. Krust, P. Clement-lacroix, D. Minet et al., Deletion of estrogen receptors reveals a regulatory role for estrogen receptors-?? in bone remodeling in females but not in males, Bone, vol.30, issue.1, pp.18-25, 2002.
DOI : 10.1016/S8756-3282(01)00643-3

K. Lee, H. Jessop, R. Suswillo, G. Zaman, and L. Lanyon, Endocrinology: Bone adaptation requires oestrogen receptor-??, Nature, vol.424, issue.6947, p.389, 2003.
DOI : 10.1038/424389a

L. Saxon and C. Turner, Estrogen receptor ??: the antimechanostat?, Bone, vol.36, issue.2, pp.185-192, 2005.
DOI : 10.1016/j.bone.2004.08.003

M. Kian-tee, I. Rogatsky, C. Tzagarakis-foster, A. Cvoro, J. An et al., Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors ?? and ??, Molecular Biology of the Cell, vol.15, issue.3, pp.1262-1272, 2004.
DOI : 10.1091/mbc.E03-06-0360

M. Allen, J. Hock, and D. Burr, Periosteum: biology, regulation, and response to osteoporosis therapies, Bone, vol.35, issue.5, pp.1003-1012, 2004.
DOI : 10.1016/j.bone.2004.07.014

E. Orwoll, Toward an Expanded Understanding of the Role of the Periosteum in Skeletal Health, Journal of Bone and Mineral Research, vol.198, issue.6, pp.949-954, 2003.
DOI : 10.1359/jbmr.2003.18.6.949

K. Uusi-rasi, T. Beck, L. Semanick, M. Daphtary, G. Crans et al., Structural effects of raloxifene on the proximal femur: results from the multiple outcomes of raloxifene evaluation trial, Osteoporosis International, vol.36, issue.Suppl 5, pp.575-586, 2006.
DOI : 10.1007/s00198-005-0028-3

E. Siris, S. Harris, R. Eastell, J. Zanchetta, S. Goemaere et al., Skeletal Effects of Raloxifene After 8 Years: Results from the Continuing Outcomes Relevant to Evista (CORE) Study, Journal of Bone and Mineral Research, vol.8, issue.Suppl 1, pp.1514-1524, 2005.
DOI : 10.1359/JBMR.050509

S. Harris, N. Watts, H. Genant, C. Mckeever, T. Hangartner et al., Effects of Risedronate Treatment on Vertebral and Nonvertebral Fractures in Women With Postmenopausal Osteoporosis<SUBTITLE>A Randomized Controlled Trial</SUBTITLE>, JAMA, vol.282, issue.14, pp.1344-1352, 1999.
DOI : 10.1001/jama.282.14.1344

D. Karpf, D. Shapiro, E. Seeman, K. Ensrud, C. Johnston et al., Prevention of Nonvertebral Fractures by Alendronate, JAMA, vol.277, issue.14, 1997.
DOI : 10.1001/jama.1997.03540380073035

S. Komatsubara, S. Mori, T. Mashiba, J. Li, K. Nonaka et al., Suppressed Bone Turnover by Long-Term Bisphosphonate Treatment Accumulates Microdamage but Maintains Intrinsic Material Properties in Cortical Bone of Dog Rib, Journal of Bone and Mineral Research, vol.23, issue.6, pp.999-1005, 2004.
DOI : 10.1359/JBMR.040126

R. Balena, A. Markatos, J. Seedor, M. Gentile, C. Stark et al., Long-term safety of the aminobisphosphonate alendronate in adult dogs. II. Histomorphometric analysis of the L5 vertebrae, J Pharmacol Exp Ther, vol.276, pp.277-283, 1996.

R. Balena, B. Toolan, M. Shea, A. Markatos, E. Myers et al., The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates., Journal of Clinical Investigation, vol.92, issue.6, pp.2577-2586, 1993.
DOI : 10.1172/JCI116872

J. Gasser, P. Ingold, A. Rebmann, M. Susa, and J. Green, Inhibition of FPP-synthase in osteoblasts may explain the blunting of the bone anabolic response to PTH observed after chronic exposure of rats to bisphosphonates, Bone, vol.38, issue.3, p.50, 2006.
DOI : 10.1016/j.bone.2005.12.044

S. Bare, S. Recker, R. Recker, and D. Kimmel, Influence of alendronate on periosteal and endocortical bone formation in the ilium of osteoporotic women, J Bone Miner Res, vol.20, p.414, 2005.

R. Recker, R. Weinstein, C. Chesnut, R. Schimmer, P. Mahoney et al., Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study, Osteoporosis International, vol.15, issue.3, pp.231-237, 2004.
DOI : 10.1007/s00198-003-1530-0

H. Alhlborg, O. Johnell, C. Turner, G. Rannevik, and M. Karlsson, Bone Loss and Bone Size after Menopause, New England Journal of Medicine, vol.349, issue.4, pp.327-334, 2003.
DOI : 10.1056/NEJMoa022464

P. Sambrook, P. Geusens, C. Ribot, J. Solimano, J. Ferrer-barriendos et al., Alendronate produces greater effects than raloxifene on bone density and bone turnover in postmenopausal women with low bone density: results of EFFECT (EFficacy of FOSAMAXR versus EVISTARComparison Trial) International1, Journal of Internal Medicine, vol.17, issue.4, pp.503-511, 2004.
DOI : 10.1001/jama.283.10.1318

M. Allen, K. Iwata, M. Sato, and D. Burr, Raloxifene enhances vertebral mechanical properties independent of bone density, Bone, vol.39, issue.5, 2006.
DOI : 10.1016/j.bone.2006.05.007

D. Black, J. Bilezikian, K. Ensrud, S. Greenspan, L. Palermo et al., One Year of Alendronate after One Year of Parathyroid Hormone (1???84) for Osteoporosis, New England Journal of Medicine, vol.353, issue.6, pp.555-565, 2005.
DOI : 10.1056/NEJMoa050336

D. Black, S. Greenspan, K. Ensrud, L. Palermo, J. Mcgowan et al., The Effects of Parathyroid Hormone and Alendronate Alone or in Combination in Postmenopausal Osteoporosis, New England Journal of Medicine, vol.349, issue.13, pp.1207-1215, 2003.
DOI : 10.1056/NEJMoa031975

J. Finkelstein, A. Hayes, J. Hunzelman, J. Wyland, H. Lee et al., The Effects of Parathyroid Hormone, Alendronate, or Both in Men with Osteoporosis, New England Journal of Medicine, vol.349, issue.13, pp.1216-1226, 2003.
DOI : 10.1056/NEJMoa035725

R. Recker, P. Masarachia, A. Santora, T. Howard, P. Chavassieux et al., Trabecular bone microarchitecture after alendronate treatment of osteoporotic women, Current Medical Research and Opinion, vol.21, issue.2, pp.185-194, 2005.
DOI : 10.1185/030079904X20259

P. Wolvekamp, The many faces of elbow dysplasia, Proceedings from the 27th World Small Animal Veterinary Association Congress, 2002.